Tests glucose sensor monitoring for type 2 diabetes during pregnancy
Compares a continuous glucose sensor with fingerstick checks in pregnant women with type 2 diabetes.
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, Chapel Hill, Greenville, Houston, Philadelphia, Portland, and San Diego, United StatesSee the 7 sites
- Trial code
- Registry title
- CGM for Management of Type 2 Diabetes in Pregnancy
- Status
- Recruiting
- People taking part
- 564 people, planned
- Started
- 8 Apr 2025
- Expected to end
- Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- CGM
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women aged 18-50 who have type 2 diabetes and are 6 to less than 23 weeks pregnant.
- Age
- 18 to 50 years
- Sex
- Women only
- Disease stage
- Type 2 diabetes treated with daily insulin injections or diabetes pills, diagnosed before pregnancy or before 14 weeks of pregnancy with hemoglobin A1c 6.5% (48 mmol/mol) or greater. Pregnant with a viable fetus at 6 to less than 23 weeks.
- Biomarker or test result
- Hemoglobin A1c 6.5% (48 mmol/mol) or greater for diabetes diagnosed before 14 weeks of pregnancy.
Main reasons for not taking part
- Cannot or will not wear a continuous glucose monitor because of adhesive intolerance or skin conditions
- Twins or more (multiple gestation)
- Major fetal anomaly or two or more minor fetal anomalies
- Planned delivery outside the study consortium
- Took part in this trial in a previous pregnancy
This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant with viable fetus at 6 to less than 23 weeks gestation
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater
- Pregnant with viable fetus at 6 to less than 23 weeks gestation
- Maternal age 18-50 years old
Who cannot take part
- Participation in this trial in a previous pregnancy
- Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions
- Multiple gestation
- Major fetal anomaly or two or more minor fetal anomalies
- Planned delivery outside study consortium
- Participating in another conflicting interventional study
- Patient unable to consent
- Physician refusal for other reasons
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesContact: Ashley BattarbeeTaking people
- University of North Carolina, Chapel HillChapel Hill, United StatesContact: Kim Boggess, MDTaking people
- Prisma Health Greenville Memorial HospitalGreenville, United StatesContact: Daniel Pasko, MDTaking people
- University of Texas Health Science Center at HoustonHouston, United StatesContact: Michal Fishel Bartal, MDTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Celeste Durnwald, MDTaking people
- Oregon Health and Science UniversityPortland, United StatesContact: Amy Valent, DO, MCRTaking people
- University of California At San DiegoSan Diego, United StatesContact: Gladys Ramos, MDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:
Read full original descriptionShow less
1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications?
Participants will:
1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis
The 2 groups in the trial
- Continuous Glucose MonitoringTreatment being tested
Real-time continuous glucose monitoring
Treatment: CGM
- Self-Monitoring of Blood GlucoseNo study treatment, for comparison
Self-monitoring of blood glucose (standard of care)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy
- Plain-language title
- Tests glucose sensor monitoring for type 2 diabetes during pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06628453, who can take part
- Record updated
- 29 June 2026